[stock_market_widget type=”card” template=”basic2″ assets=”ARGX” realtime=”true” api=”yahoo-finance”]
argenx SE (NASDAQ: ARGX) has announced that it had agreed to buy Forte Biosciences, Inc. (NASDAQ: FBRX) for $77 a share in cash, a transaction valuing the smaller company at roughly $2.2 billion. The two companies announced the agreement together and held an investor call this morning to walk analysts through the terms.
The mechanics of the deal are fairly standard for a cash acquisition of this size. A subsidiary of argenx will run a tender offer for all outstanding Forte shares, and once a majority of shares are tendered, the companies will complete a merger so that any remaining shareholders receive the same $77 per share. argenx said the purchase will be funded entirely from cash on hand, meaning the deal does not depend on outside financing, and both boards have already approved it. The transaction is expected to close in the third quarter of 2026, pending customary conditions including antitrust clearance under the Hart Scott Rodino Act.
What makes the price notable is not just the dollar figure but how quickly it materialized. The $77 offer represents about a 40% premium to Forte’s closing price on July 24, but an 86% premium to the stock’s volume weighted average price going back to July 9, 2026, the day Forte released positive Phase 1b results in vitiligo. In other words, most of the value in this deal was created in the space of about two weeks, once a single clinical trial readout changed how the market viewed the company.
Forte Biosciences is a clinical stage biopharmaceutical company, meaning it has no approved, commercially sold drugs. Its value rests almost entirely on one experimental medicine, FB102, a first in class antibody that targets a receptor called CD122. FB102 is designed to interfere with the activity of certain T cells and natural killer cells that are believed to drive autoimmune disease. The company has reported statistically significant Phase 1b results for FB102 in two separate conditions, vitiligo (a disease that causes patches of skin to lose pigment) and celiac disease, an autoimmune reaction to gluten. Additional Phase 2 data in celiac disease is expected later this year.
For argenx, the appeal is straightforward. The company already has an established immunology business built around its approved therapy efgartigimod, along with several other programs in development, including empasiprubart, adimanebart and ARGX-121. FB102 gives argenx a mechanism it did not previously have in that portfolio, aimed at diseases where no biologic treatment has yet reached the market. Company leadership described the acquisition as consistent with its stated goal of expanding into new areas of immune disease treatment through 2030.
This deal is also a useful illustration of how binary, trial driven outcomes work in biotech investing. A company with a single meaningful asset and no revenue can go from a market value near $1 billion to a $2.2 billion acquisition target in the space of one trading session, entirely on the strength of clinical data. That same structure cuts both ways: had the Phase 1b results in vitiligo disappointed, Forte’s value could easily have moved in the opposite direction. The Forte Biosciences transaction shows how much weight a single set of trial results can carry for a company built around one experimental drug, and how quickly that weight can translate into a takeover once larger, cash rich companies take notice.
